FDA tells Boston it can relaunch SOX stent system
This article was originally published in Clinica
Executive Summary
The US FDA has approved for sale a redesigned version of Boston Scientific's NIR with SOX over-the-wire coronary stent system. This brings welcome news to the company after a turbulent 18 months, which has seen Boston subject to a product recall, the discovery of accounting irregularities in Japan and an investigation by the US Justice Department.